# Freiburg ZNS-NHL Study

> **NCT00647049** · PHASE2 · UNKNOWN · sponsor: **University Hospital Freiburg** · enrollment: 78 (estimated)

## Conditions studied

- Primary Non Hodgkin Lymphoma of the Central Nervous System

## Interventions

- **DRUG:** methotrexate
- **DRUG:** Rituximab
- **DRUG:** Cytarabine
- **DRUG:** Thiotepa
- **DRUG:** Carmustin

## Key facts

- **NCT ID:** NCT00647049
- **Lead sponsor:** University Hospital Freiburg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-01
- **Primary completion:** 2013-05
- **Final completion:** 2013-08
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2009-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00647049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00647049, "Freiburg ZNS-NHL Study". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00647049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*